4.4 Article

Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus

期刊

CURRENT ATHEROSCLEROSIS REPORTS
卷 14, 期 1, 页码 60-69

出版社

CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-011-0221-0

关键词

Weight loss; Weight management; Obesity; Type 2 diabetes; Pharmacotherapy; Glycemic control; Weight-centric management of type 2 diabetes

资金

  1. Atkins Foundation
  2. Amylin
  3. MetaProteomics
  4. Orexigen
  5. Novo Nordisk
  6. F. Hoffman-La Roche
  7. Pfizer
  8. Merck
  9. Arena
  10. VIVUS
  11. Schering-Plough
  12. TransTech Pharma
  13. MetaCure
  14. Metabolous Pharmaceuticals

向作者/读者索取更多资源

Overweight and obesity are now recognized as leading causes of diseases such as type 2 diabetes, hypertension, hyperlipidemia, and ultimately, cardiovascular disease. Despite the serious consequences, roughly two thirds of Americans are presently classified as overweight, and about one third are classified as obese. Weight loss via lifestyle modification and pharmacotherapy can promote improvement in many of these obesity-related conditions. This review addresses recent advances in pharmacotherapy for the management of obesity and obesity-related co-morbidities, with a focus on the management of obesity specifically in individuals with type 2 diabetes. Emphasis is also placed on a proposed paradigm shift from the glucose-centric to the weight-centric management of type 2 diabetes mellitus.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据